• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells.

作者信息

Karschnia Philipp, Miller Kevin C, Yee Andrew J, Rejeski Kai, Johnson P Connor, Raje Noopur, Frigault Matthew J, Dietrich Jorg

机构信息

Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.

Section for Neuro-Oncology, Department of Neurosurgery, Ludwig Maximilian University, Munich, Germany.

出版信息

Blood. 2023 Oct 5;142(14):1243-1248. doi: 10.1182/blood.2023020571.

DOI:10.1182/blood.2023020571
PMID:37471607
Abstract
摘要

相似文献

1
Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells.采用靶向BCMA的嵌合抗原受体T细胞进行过继性免疫治疗后的神经毒性。
Blood. 2023 Oct 5;142(14):1243-1248. doi: 10.1182/blood.2023020571.
2
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原免疫疗法对多发性骨髓瘤具有广阔的应用前景。
Ann Hematol. 2019 Apr;98(4):813-822. doi: 10.1007/s00277-018-03592-9. Epub 2019 Jan 28.
3
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.经基因修饰表达抗 B 细胞成熟抗原嵌合抗原受体的 T 细胞可引起预后不良的复发性多发性骨髓瘤缓解。
J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.
4
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.γ-分泌酶抑制剂联合 BCMA 嵌合抗原受体 T 细胞免疫疗法治疗复发或难治性多发性骨髓瘤患者的 1 期、首次人体试验。
Lancet Oncol. 2023 Jul;24(7):811-822. doi: 10.1016/S1470-2045(23)00246-2.
5
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.同种异体嵌合抗原受体 T 细胞靶向 BCMA 治疗多发性骨髓瘤的临床前评估。
Mol Ther. 2019 Jun 5;27(6):1126-1138. doi: 10.1016/j.ymthe.2019.04.001. Epub 2019 Apr 8.
6
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原表达的血液系统恶性肿瘤。
Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.
7
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma.抗 TACI 单靶点和双靶点 CAR T 细胞克服多发性骨髓瘤中 BCMA 抗原丢失。
Nat Commun. 2023 Nov 18;14(1):7509. doi: 10.1038/s41467-023-43416-7.
8
Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤患者接受成熟抗原（BCMA）嵌合抗原受体（CAR）-T细胞（HDS269B）治疗后的后续抗骨髓瘤治疗。
Am J Hematol. 2022 Dec;97(12):E478-E481. doi: 10.1002/ajh.26745. Epub 2022 Oct 17.
9
BCMA CAR-T cells in multiple myeloma-ready for take-off?BCMA CAR-T 细胞治疗多发性骨髓瘤：一飞冲天？
Leuk Lymphoma. 2024 Feb;65(2):143-157. doi: 10.1080/10428194.2023.2276676. Epub 2024 Jan 24.
10
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.抗 BCMA CAR T 细胞疗法 bb2121 治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.

引用本文的文献

1
Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity.癌症治疗引起的外周和中枢神经毒性的机制与治疗
Nat Rev Cancer. 2025 Sep 9. doi: 10.1038/s41568-025-00863-2.
2
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma.大B细胞淋巴瘤中CD19嵌合抗原受体T细胞疗法的国际代谢预后指数的优化与验证
Blood Cancer J. 2025 Aug 26;15(1):144. doi: 10.1038/s41408-025-01338-1.
3
Noncanonical and mortality-defining toxicities of CAR T cell therapy.嵌合抗原受体T细胞疗法的非典型及决定死亡率的毒性作用
Nat Med. 2025 Jul 16. doi: 10.1038/s41591-025-03813-5.
4
Neurological complications of CAR T cell therapy for cancers.嵌合抗原受体（CAR）T细胞疗法治疗癌症的神经并发症
Nat Rev Neurol. 2025 Jun 25. doi: 10.1038/s41582-025-01112-8.
5
Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma.芦可替尼是治疗多发性骨髓瘤中cilta-cabtagene autoleucel相关帕金森症的有效疗法。
J Hematol. 2025 Jun;14(3):146-151. doi: 10.14740/jh2046. Epub 2025 Apr 22.
6
Toxicities Associated with CAR-T Cell Therapies.与嵌合抗原受体T细胞疗法相关的毒性
Mediterr J Hematol Infect Dis. 2025 May 1;17(1):e2025039. doi: 10.4084/MJHID.2025.039. eCollection 2025.
7
Neurological complications associated with chimeric antigen receptor T cell therapy.嵌合抗原受体T细胞疗法相关的神经并发症
J Cereb Blood Flow Metab. 2025 May 2:271678X251332492. doi: 10.1177/0271678X251332492.
8
CAR-T for multiple myeloma: practice pearls.嵌合抗原受体T细胞疗法治疗多发性骨髓瘤：实用要点
Bone Marrow Transplant. 2025 Apr 17. doi: 10.1038/s41409-025-02582-6.
9
Deep insight into cytokine storm: from pathogenesis to treatment.深入洞察细胞因子风暴：从发病机制到治疗。
Signal Transduct Target Ther. 2025 Apr 16;10(1):112. doi: 10.1038/s41392-025-02178-y.
10
Long-Term Cognitive Outcomes in Adult Patients Receiving Chimeric Antigen Receptor T-Cell Therapies.接受嵌合抗原受体T细胞疗法的成年患者的长期认知结果
Transplant Cell Ther. 2025 Apr;31(4):236.e1-236.e13. doi: 10.1016/j.jtct.2025.01.886. Epub 2025 Jan 25.